Sunesis Pharma (SNSS) received a Hold rating and a $0.50 price target from H.C. Wainwright analyst Andrew Fein today. The company’s shares closed yesterday at $0.32, close to its 52-week low of $0.30.
Fein commented:
“Valuation and risks to achievement of target price. Our price target of $0.50/share is based on an equally-weighted composite of: (a) $0.60/share, as a 25x multiple of taxed and diluted $0.38 discounted back to FY19 at 35% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $0.40/share (discounted cash flow analysis using a 13.5% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 3.7% and a 38.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and ACADIA Pharmaceuticals Inc.
Currently, the analyst consensus on Sunesis Pharma is a Moderate Buy with an average price target of $7.
See today’s analyst top recommended stocks >>
Based on Sunesis Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $6.51 million. In comparison, last year the company had a GAAP net loss of $10.16 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia.
